Moderna 大跌 10%，结束三日连升。Moderna 年内大涨逾600%，其mRNA癌症疫苗与K药联合疗法的III期阳性结果重塑其肿瘤管线叙事。即将召开的ESMO年会及完整数据成为关键催化剂。尽管资本看好mRNA平台潜力，但巨额亏损与高市销率令估值承压，分析师普遍认为当前股价已过度消化未来成功。
Moderna 大跌 10%，结束三日连升。Moderna 年内大涨逾600%，其mRNA癌症疫苗与K药联合疗法的III期阳性结果重塑其肿瘤管线叙事。即将召开的ESMO年会及完整数据成为关键催化剂。尽管资本看好mRNA平台潜力，但巨额亏损与高市销率令估值承压，分析师普遍认为当前股价已过度消化未来成功。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
